Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 22 04:00PM ET
0.1798
Dollar change
-0.0013
Percentage change
-0.72
%
Index- P/E- EPS (ttm)-0.58 Insider Own14.99% Shs Outstand31.14M Perf Week-5.37%
Market Cap5.60M Forward P/E- EPS next Y-0.40 Insider Trans0.00% Shs Float26.47M Perf Month16.00%
Income-11.02M PEG- EPS next Q-0.08 Inst Own16.41% Short Float4.61% Perf Quarter3.63%
Sales9.00M P/S0.62 EPS this Y74.58% Inst Trans-0.06% Short Ratio0.62 Perf Half Y-31.89%
Book/sh-0.10 P/B- EPS next Y-13.21% ROA-75.82% Short Interest1.22M Perf Year-89.36%
Cash/sh0.25 P/C0.72 EPS next 5Y- ROE-1277.01% 52W Range0.13 - 2.19 Perf YTD2.68%
Dividend Est.- P/FCF- EPS past 5Y34.33% ROI- 52W High-91.79% Beta0.80
Dividend TTM- Quick Ratio0.71 Sales past 5Y-50.00% Gross Margin99.83% 52W Low43.27% ATR (14)0.01
Dividend Ex-Date- Current Ratio0.71 EPS Y/Y TTM60.71% Oper. Margin-145.97% RSI (14)44.63 Volatility6.18% 9.04%
Employees18 Debt/Eq- Sales Y/Y TTM-100.00% Profit Margin-122.49% Recom1.67 Target Price4.00
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q197.43% Payout- Rel Volume0.34 Prev Close0.18
Sales Surprise-100.00% EPS Surprise546.15% Sales Q/Q- EarningsNov 09 AMC Avg Volume1.97M Price0.18
SMA20-7.48% SMA50-1.26% SMA200-35.94% Trades Volume662,378 Change-0.72%
Date Action Analyst Rating Change Price Target Change
Apr-16-21Upgrade BTIG Research Neutral → Buy $14
Feb-10-21Initiated Maxim Group Buy $24
Dec-23-19Reiterated H.C. Wainwright Buy $15 → $18
Mar-01-19Reiterated Needham Buy $7
Jun-13-17Reiterated Stifel Buy $14 → $6
Dec-21-16Initiated Jefferies Buy $10
Feb-01-16Resumed Oppenheimer Outperform
Jul-29-15Initiated ROTH Capital Buy $18
Mar-02-15Reiterated Stifel Buy $16 → $20
Mar-02-15Reiterated Oppenheimer Outperform $22 → $26
Dec-20-23 08:00AM
Nov-21-23 07:55AM
07:32AM
Nov-20-23 08:00AM
Nov-13-23 09:29AM
08:47AM Loading…
Nov-12-23 08:47AM
Nov-10-23 07:45AM
Nov-09-23 04:58PM
04:02PM
Oct-31-23 04:02PM
Sep-18-23 08:00AM
Sep-05-23 04:02PM
Aug-25-23 07:20AM
Aug-15-23 08:43AM
Aug-14-23 07:00PM
04:02PM Loading…
04:02PM
Aug-02-23 04:05PM
Jul-11-23 08:00AM
Jun-20-23 08:00AM
Jun-16-23 08:00AM
Jun-15-23 08:00AM
Jun-02-23 08:00AM
May-30-23 08:00AM
May-11-23 11:24AM
May-10-23 04:38PM
04:02PM
May-03-23 04:02PM
Apr-25-23 07:41AM
Apr-06-23 08:30AM
Mar-14-23 12:00PM
02:26AM Loading…
Mar-10-23 02:26AM
Mar-09-23 05:49AM
Mar-08-23 04:02PM
Feb-28-23 04:02PM
Jan-20-23 06:55AM
Jan-10-23 08:30AM
Dec-27-22 08:00AM
Dec-14-22 11:29AM
08:00AM
Nov-21-22 08:00AM
Nov-14-22 04:02PM
Oct-31-22 08:00AM
Oct-06-22 08:30AM
08:00AM
Sep-14-22 08:00AM
Sep-07-22 08:00AM
Sep-06-22 08:00AM
Aug-29-22 08:00PM
11:45AM
08:00AM
Aug-10-22 04:02PM
08:00AM
Aug-08-22 08:00AM
Jul-27-22 08:05AM
Jul-26-22 08:05AM
Jun-02-22 08:05AM
May-16-22 08:05AM
May-11-22 04:02PM
May-04-22 08:05AM
Apr-19-22 08:05AM
Apr-08-22 05:02PM
Mar-23-22 08:05AM
Mar-15-22 04:02PM
Mar-11-22 08:05AM
Mar-10-22 08:05AM
Mar-04-22 08:05AM
Feb-02-22 08:05AM
Jan-05-22 08:05AM
Dec-27-21 08:00AM
Nov-29-21 08:05AM
Nov-11-21 08:05AM
Nov-03-21 04:02PM
Oct-27-21 08:05AM
Oct-13-21 08:00AM
Oct-11-21 01:27PM
08:00AM
Sep-13-21 08:05AM
Sep-07-21 08:05AM
07:29AM
Sep-02-21 08:05AM
Aug-11-21 04:02PM
Aug-09-21 08:05AM
Aug-03-21 08:05AM
Jul-28-21 08:05AM
Jul-21-21 10:30PM
05:27PM
Jul-20-21 08:05AM
Jun-30-21 08:05AM
Jun-29-21 08:05AM
Jun-28-21 01:04PM
Jun-18-21 10:08AM
Jun-04-21 09:01AM
Jun-01-21 08:05AM
May-25-21 08:05AM
May-20-21 08:05AM
May-05-21 04:03PM
02:45PM
08:25AM
May-03-21 08:05AM
Apr-28-21 08:05AM
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
THEUER CHARLESPresident and CEOApr 27Buy0.7547,00035,250399,417Apr 28 06:00 AM
THEUER CHARLESPresident and CEOApr 26Buy0.663,9992,639352,417Apr 28 06:00 AM
Opaleye Management Inc.10% OwnerMar 09Buy1.38174,508240,8214,324,508Mar 13 04:05 PM
THEUER CHARLESPresident and CEOMar 01Buy1.524,8007,296344,918Mar 02 06:24 AM
THEUER CHARLESPresident and CEOFeb 28Buy1.52200304340,118Mar 02 06:24 AM